SAMSARA BIOCAPITAL, LLC
SAMSARA BIOCAPITAL, LLC is a Series A, Series B and Series C+ fund in the US writing $10M–$100M checks into healthcare-tech.
- Stages
- Series A, Series B, Series C+
- Sectors
- healthcare-tech
- Check size
- $10M–$100M
- Invests in
- US-wide
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2016
- Assets under management
- $1.9B
- Website
- samsaracap.com
Thesis
Samsara BioCapital is a venture capital firm founded in 2016 that focuses on translating cutting-edge science into transformative medicines for patients. They invest across all stages of public and private life science companies, primarily in Series B rounds in United States-based startups, but also in Series A and other stages. The firm seeks to invest in the healthcare sector across the United States, typically taking large, concentrated positions in securities of life sciences companies with the potential for significant value creation over the long term. Their investment strategy is focused on long-term value creation, believing that innovation and meaningful patient impact will drive attractive risk-adjusted returns. They integrate factors to develop an investment thesis focused on intrinsic value and a capital formation plan to achieve significant milestones. Identifying specific management talent that can successfully develop and commercialize the company's products is critical to their investment process. Samsara BioCapital has approximately $1.9 billion in AUM as of March 31, 2025, and a fund size of $310 million.
Common questions
Does SAMSARA BIOCAPITAL, LLC invest at the Series A stage?
Yes. SAMSARA BIOCAPITAL, LLC lists Series A, Series B and Series C+ among the stages it invests in.
What check size does SAMSARA BIOCAPITAL, LLC write?
SAMSARA BIOCAPITAL, LLC writes $10M–$100M checks.
Where does SAMSARA BIOCAPITAL, LLC invest?
SAMSARA BIOCAPITAL, LLC invests in the US.